Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma

1Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3: 1683-91. doi: 10.1001/jamaoncol.2017.3055Global Burden of Disease Liver Cancer Collaboration Akinyemiju T Abera S Ahmed M Alam N Alemayohu MA et al The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015 JAMA Oncol 2017 3 1683 91 10.1001/jamaoncol.2017.3055582427528983565Open DOISearch in Google Scholar

2European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 2018 69 182 236 10.1016/j.jhep.2018.03.01929628281Open DOISearch in Google Scholar

3Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv238-55. doi: 10.1093/annonc/mdy308Vogel A Cervantes A Chau I Daniele B Llovet JM Meyer T et al Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2018 29 iv238–55 10.1093/annonc/mdy30830285213Open DOISearch in Google Scholar

4Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5. doi: 10.1016/j.jhep.2012.01.008Burrel M Reig M Forner A Barrufet M de Lope CR Tremosini S et al Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads Implications for clinical practice and trial design. J Hepatol 2012 56 1330 5 10.1016/j.jhep.2012.01.00822314428Open DOISearch in Google Scholar

5European Association for the Study of the Liver, European Organisation for Research and Treatement of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J hepatol 2012; 56: 908-43. doi: 10.1016/j.jhep.2011.12.001European Association for the Study of the Liver, European Organisation for Research and Treatement of Cancer EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma J hepatol 2012 56 908 43 10.1016/j.jhep.2011.12.00122424438Open DOISearch in Google Scholar

6Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol 2012; 81: 1173-8. doi: 10.1016/j.ejrad.2011.03.046Bargellini I Sacco R Bozzi E Bertini M Ginanni B Romano A et al Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study Eur J Radiol 2012 81 1173 8 10.1016/j.ejrad.2011.03.04621466931Open DOISearch in Google Scholar

7Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81. doi: 10.1016/j.jhep.2006.10.020Varela M Real MI Burrel M Forner A Sala M Brunet M et al Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 2007 46 474 81 10.1016/j.jhep.2006.10.02017239480Open DOISearch in Google Scholar

8Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61: 184-90. doi: 10.1002/hep.27443Giannini EG Farinati F Ciccarese F Pecorelli A Rapaccini GL Di Marco M et al Prognosis of untreated hepatocellular carcinoma Hepatology 2015 61 184 90 10.1002/hep.2744325234419Open DOISearch in Google Scholar

9Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016; 64: 106-16. doi: 10.1002/hep.28453Lencioni R de Baere T Soulen MC Rilling WS Geschwind JF Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data Hepatology 2016 64 106 16 10.1002/hep.2845326765068Open DOISearch in Google Scholar

10Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 2016; 48: 571-7. doi: 10.1016/j.dld.2016.02.005Facciorusso A Di Maso M Muscatiello N Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis Dig Liver Dis 2016 48 571 7 10.1016/j.dld.2016.02.00526965785Open DOISearch in Google Scholar

11Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52. doi: 10.1007/s00270-009-9711-7Lammer J Malagari K Vogl T Pilleul F Denys A Watkinson A et al Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 2010 33 41 52 10.1007/s00270-009-9711-7281679419908093Open DOISearch in Google Scholar

12Floridi C, Radaelli A, Abi-Jaoudeh N, Grass M, Lin M, Chiaradia M, et al. C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications. Radiol Med 2014; 119: 521-32. doi: 10.1007/s11547-014-0429-5Floridi C Radaelli A Abi-Jaoudeh N Grass M Lin M Chiaradia M et al C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications Radiol Med 2014 119 521 32 10.1007/s11547-014-0429-5420996525012472Open DOISearch in Google Scholar

13Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016; 50: 418-26. doi: 10.1515/raon-2015-0045Popovic P Stabuc B Jansa R Garbajs M Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control Radiol Oncol 2016 50 418 26 10.1515/raon-2015-0045512057427904450Open DOISearch in Google Scholar

14Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol 2012; 35: 765-74. doi: 10.1007/s00270-012-0423-zBasile A Carrafiello G Ierardi AM Tsetis D Brountzos E Quality-improvement guidelines for hepatic transarterial chemoembolization Cardiovasc Intervent Radiol 2012 35 765 74 10.1007/s00270-012-0423-z22648700Open DOISearch in Google Scholar

15Lencioni R, Llovet J. Modified RECIST (mRECIST) Assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60. doi: 10.1055/s-0030-1247132Lencioni R Llovet J Modified RECIST (mRECIST) Assessment for hepatocellular carcinoma Semin Liver Dis 2010 30 52 60 10.1055/s-0030-124713220175033Open DOISearch in Google Scholar

16Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-14. doi: 10.1016/S0140-6736(11)61347-0Forner A Reig M Bruix J Hepatocellular carcinoma Lancet 2018 391 1301 14 10.1016/S0140-6736(11)61347-022353262Open DOISearch in Google Scholar

17Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. doi: 10.1053/jhep.2003.50047Llovet J Bruix J Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 2003 37 429 42 10.1053/jhep.2003.5004712540794Open DOISearch in Google Scholar

18Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl 3): S258-63. doi: 10.4254/wjh.v7.i9.1184Piscaglia F Bolondi L The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010 42Suppl 3 S258 63 10.4254/wjh.v7.i9.1184443849326019734Open DOISearch in Google Scholar

19Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 2020; 72: 198-212. doi: 10.1002/hep.31022Han G Berhane S Toyoda H Bettinger D Elshaarawy O Chan AWH et al Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach Hepatology 2020 72 198 212 10.1002/hep.31022749633431698504Open DOISearch in Google Scholar

20Xiao J, Li G, Lin S, He K, Lai H, Mo X, et al. Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. Int J Clin Exp Pathol 2014; 7: 1114-23. PMID: 24696728Xiao J Li G Lin S He K Lai H Mo X et al Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization Int J Clin Exp Pathol 2014 7 1114 23 PMID: 24696728Search in Google Scholar

21Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat? Radiology 2021; 298: 680-92. doi: 10.1148/radiol.2021202289Chen S Peng Z Zhang Y Chen M Li J Guo R et al Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat? Radiology 2021 298 680 92 10.1148/radiol.202120228933464183Open DOISearch in Google Scholar

22Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, et al. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis 2010; 42: 515-9. doi: 10.1016/j.dld.2009.09.012Olivo M Valenza F Buccellato A Scala L Virdone R Sciarrino E et al Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors Dig Liver Dis 2010 42 515 9 10.1016/j.dld.2009.09.01219914153Open DOISearch in Google Scholar

23Suk Oh J, Jong Chun H, Gil Choi B, Giu Lee H. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vasc Interv Radiol 2013; 24: 483-9. doi: 10.1016/j.jvir.2013.01.001Suk Oh J Jong Chun H Gil Choi B Giu Lee H Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response J Vasc Interv Radiol 2013 24 483 9 10.1016/j.jvir.2013.01.00123452553Open DOISearch in Google Scholar

24Ikeda M, Inaba Y, Tanaka T, Sugawara S, Kodama Y, Aramaki T, et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. [Abstract]. JCO 2020; 38(15 Suppl): 4518. doi: 10.1200/jco.2020.38.15_suppl.4518Ikeda M Inaba Y Tanaka T Sugawara S Kodama Y Aramaki T et al A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study [Abstract]. JCO 2020 3815 Suppl 4518 10.1200/jco.2020.38.15_suppl.4518Open DOISearch in Google Scholar

25Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol 201; 28: 207-11. doi: 10.1055/s-0031-1280666Dhand S Gupta R Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome Semin Intervent Radiol 201 28 207 11 10.1055/s-0031-1280666319332422654264Open DOISearch in Google Scholar

26Rashid M, Kwok CS, Pancholy S, Chugh S, Kedev SA, Bernat I, et al. Radial artery occlusion after transradial interventions: a systematic review and meta-analysis. J Am Heart Assoc 2016; 5: e002686. doi: 10.1161/JAHA.115.002686Rashid M Kwok CS Pancholy S Chugh S Kedev SA Bernat I et al Radial artery occlusion after transradial interventions: a systematic review and meta-analysis J Am Heart Assoc 2016 5 e002686 10.1161/JAHA.115.002686485938626811162Open DOISearch in Google Scholar

27Zach V, Rapaport B, Yoo JY, Goldfeder L, Weinberger J. Multiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate. J Stroke Cerebrovasc Dis 2012; 21: 217-24. doi: 10.1016/j.jstrokecerebrovas-dis.2010.08.001Zach V Rapaport B Yoo JY Goldfeder L Weinberger J Multiple ischemic strokes after transcatheter arterial chemoembolization for hepatocellular carcinoma with a radiographic and pathological correlate J Stroke Cerebrovasc Dis 2012 21 217 24 10.1016/j.jstrokecerebrovas-dis.2010.08.001Open DOISearch in Google Scholar

28Onizuka H, Sueyoshi E, Ishimaru H, Sakamoto I, Uetani M. Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome. Abdom Radiol (NY) 2017; 42: 2544-50. doi: 10.1007/s00261-017-1168-6Onizuka H Sueyoshi E Ishimaru H Sakamoto I Uetani M Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome Abdom Radiol (NY) 2017 42 2544 50 10.1007/s00261-017-1168-628493072Open DOISearch in Google Scholar